Key Points
- iRadimed CEO Roger Susi sold 3,750 shares on May 4 at an average price of $85.69 under a pre-arranged Rule 10b5‑1 plan, trimming his stake by 0.17% while still holding 2,191,250 shares (~$187.8M).
- Company results and guidance: iRadimed beat Q1 estimates with $0.49 EPS (vs. $0.46) and $21.98M revenue, and issued FY2026 guidance of $2.060–$2.210 EPS and Q2 guidance of $0.440–$0.480.
- Dividend and analyst sentiment: the company declared a $0.20 quarterly dividend (annualized $0.80, ~0.9% yield), and analysts hold a consensus "Buy" rating with an average target price of $120.00.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 3,750 shares of the company's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $85.69, for a total transaction of $321,337.50. Following the sale, the chief executive officer directly owned 2,191,250 shares of the company's stock, valued at approximately $187,768,212.50. This represents a 0.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Trading Up 0.4%
Shares of NASDAQ IRMD opened at $86.24 on Thursday. iRadimed Corporation has a 12-month low of $50.61 and a 12-month high of $107.90. The stock has a market cap of $1.10 billion, a PE ratio of 47.13 and a beta of 0.90. The company has a 50-day moving average of $96.04 and a 200 day moving average of $94.33.
iRadimed (NASDAQ:IRMD - Get Free Report) last announced its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The company had revenue of $21.98 million during the quarter, compared to analysts' expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, sell-side analysts forecast that iRadimed Corporation will post 1.94 EPS for the current fiscal year.
iRadimed Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed's payout ratio is presently 43.72%.
Wall Street Analysts Forecast Growth
IRMD has been the topic of several recent analyst reports. Roth Mkm reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. Freedom Capital upgraded shares of iRadimed to a "strong-buy" rating in a report on Thursday, April 2nd. Finally, Lake Street Capital reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $120.00.
Check Out Our Latest Analysis on IRMD
Hedge Funds Weigh In On iRadimed
Several large investors have recently made changes to their positions in IRMD. CWM LLC lifted its holdings in shares of iRadimed by 62.2% in the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 211 shares during the last quarter. Quarry LP acquired a new position in shares of iRadimed in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC grew its stake in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 397 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 495 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new stake in shares of iRadimed in the 3rd quarter valued at $47,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.
iRadimed Company Profile
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
